EQS-News: Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
EQS-News: Benzinga / Key word (s): Science Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And ...
Targeted Oncology1d
CAR T-Cells Demonstrate Efficacy, Tolerability in Early-Relapsed DLBCL
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
labiotech3d
T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
Pharmabiz3d
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary ...
Business Insider18h
Biotech Alert: Searches spiking for these stocks today
In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma ... as well as multiple early-stage programs ...
TuHURA Biosciences: A Hold On Only The Faintest Glimmers Of Efficacy
TuHURA Biosciences, a biotech firm, is advancing DNA-based immunotherapy for cancer. Read what warrants a Hold rating for ...
pharmaphorum5d
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
The US regulator has cleared Kite's CD19-targeted CAR-T Yescarta (axicabtagene ciloleucel) for people with large B-cell lymphoma (LBCL) refractory to one earlier therapy, or who have relapsed ...